United States Angiogenesis Modulators Market Report 2017

Publisher Name :
Date: 09-Nov-2017
No. of pages: 114
Inquire Before Buying

In this report, the United States Angiogenesis Modulators market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

- The West

- Southwest

- The Middle Atlantic

- New England

- The South

- The Midwest

with sales (volume), revenue (value), market share and growth rate of Angiogenesis Modulators in these regions, from 2012 to 2022 (forecast).

United States Angiogenesis Modulators market competition by top manufacturers/players, with Angiogenesis Modulators sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

- Celgene Corporation (USA)

- Eisai Co., Ltd. (Japan)

- Amgen, Inc. (USA)

- Genentech, Inc. (USA)

- GlaxoSmithKline plc (UK)

- Bayer Pharma AG (Germany)

- Bionomics Ltd. (Australia)

- CASI Pharmaceuticals, Inc. (USA)

- AstraZeneca plc (UK)

- Eli Lilly and Company (USA)

- F.Hoffmann-La Roche AG (Switzerland)

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

- Angiogenesis Inhibitors

- Angiogenesis Stimulators

- Angiogenin

- Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

- Breast Cancer

- Colorectal Cancer

- Lung Cancer

- Prostate Cancer

- Others

If you have any special requirements, please let us know and we will offer you the report as you want.

United States Angiogenesis Modulators Market Report 2017

Table of Contents
United States Angiogenesis Modulators Market Report 2017
1 Angiogenesis Modulators Overview
1.1 Product Overview and Scope of Angiogenesis Modulators
1.2 Classification of Angiogenesis Modulators by Product Category
1.2.1 United States Angiogenesis Modulators Market Size (Sales Volume) Comparison by Type (2012-2022)
1.2.2 United States Angiogenesis Modulators Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
1.2.3 Angiogenesis Inhibitors
1.2.4 Angiogenesis Stimulators
1.2.5 Angiogenin
1.2.6 Others
1.3 United States Angiogenesis Modulators Market by Application/End Users
1.3.1 United States Angiogenesis Modulators Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
1.3.2 Breast Cancer
1.3.3 Colorectal Cancer
1.3.4 Lung Cancer
1.3.5 Prostate Cancer
1.3.6 Others
1.4 United States Angiogenesis Modulators Market by Region
1.4.1 United States Angiogenesis Modulators Market Size (Value) Comparison by Region (2012-2022)
1.4.2 The West Angiogenesis Modulators Status and Prospect (2012-2022)
1.4.3 Southwest Angiogenesis Modulators Status and Prospect (2012-2022)
1.4.4 The Middle Atlantic Angiogenesis Modulators Status and Prospect (2012-2022)
1.4.5 New England Angiogenesis Modulators Status and Prospect (2012-2022)
1.4.6 The South Angiogenesis Modulators Status and Prospect (2012-2022)
1.4.7 The Midwest Angiogenesis Modulators Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Angiogenesis Modulators (2012-2022)
1.5.1 United States Angiogenesis Modulators Sales and Growth Rate (2012-2022)
1.5.2 United States Angiogenesis Modulators Revenue and Growth Rate (2012-2022)
2 United States Angiogenesis Modulators Market Competition by Players/Suppliers
2.1 United States Angiogenesis Modulators Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Angiogenesis Modulators Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Angiogenesis Modulators Average Price by Players/Suppliers (2012-2017)
2.4 United States Angiogenesis Modulators Market Competitive Situation and Trends
2.4.1 United States Angiogenesis Modulators Market Concentration Rate
2.4.2 United States Angiogenesis Modulators Market Share of Top 3 and Top 5 Players/Suppliers
2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Angiogenesis Modulators Manufacturing Base Distribution, Sales Area, Product Type
3 United States Angiogenesis Modulators Sales (Volume) and Revenue (Value) by Region (2012-2017)
3.1 United States Angiogenesis Modulators Sales and Market Share by Region (2012-2017)
3.2 United States Angiogenesis Modulators Revenue and Market Share by Region (2012-2017)
3.3 United States Angiogenesis Modulators Price by Region (2012-2017)
4 United States Angiogenesis Modulators Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
4.1 United States Angiogenesis Modulators Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Angiogenesis Modulators Revenue and Market Share by Type (2012-2017)
4.3 United States Angiogenesis Modulators Price by Type (2012-2017)
4.4 United States Angiogenesis Modulators Sales Growth Rate by Type (2012-2017)
5 United States Angiogenesis Modulators Sales (Volume) by Application (2012-2017)
5.1 United States Angiogenesis Modulators Sales and Market Share by Application (2012-2017)
5.2 United States Angiogenesis Modulators Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities
6 United States Angiogenesis Modulators Players/Suppliers Profiles and Sales Data
6.1 Celgene Corporation (USA)
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Angiogenesis Modulators Product Category, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 Celgene Corporation (USA) Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2012-2017)
6.1.4 Main Business/Business Overview
6.2 Eisai Co., Ltd. (Japan)
6.2.2 Angiogenesis Modulators Product Category, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 Eisai Co., Ltd. (Japan) Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2012-2017)
6.2.4 Main Business/Business Overview
6.3 Amgen, Inc. (USA)
6.3.2 Angiogenesis Modulators Product Category, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 Amgen, Inc. (USA) Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2012-2017)
6.3.4 Main Business/Business Overview
6.4 Genentech, Inc. (USA)
6.4.2 Angiogenesis Modulators Product Category, Application and Specification
6.4.2.1 Product A
6.4.2.2 Product B
6.4.3 Genentech, Inc. (USA) Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2012-2017)
6.4.4 Main Business/Business Overview
6.5 GlaxoSmithKline plc (UK)
6.5.2 Angiogenesis Modulators Product Category, Application and Specification
6.5.2.1 Product A
6.5.2.2 Product B
6.5.3 GlaxoSmithKline plc (UK) Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2012-2017)
6.5.4 Main Business/Business Overview
6.6 Bayer Pharma AG (Germany)
6.6.2 Angiogenesis Modulators Product Category, Application and Specification
6.6.2.1 Product A
6.6.2.2 Product B
6.6.3 Bayer Pharma AG (Germany) Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2012-2017)
6.6.4 Main Business/Business Overview
6.7 Bionomics Ltd. (Australia)
6.7.2 Angiogenesis Modulators Product Category, Application and Specification
6.7.2.1 Product A
6.7.2.2 Product B
6.7.3 Bionomics Ltd. (Australia) Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2012-2017)
6.7.4 Main Business/Business Overview
6.8 CASI Pharmaceuticals, Inc. (USA)
6.8.2 Angiogenesis Modulators Product Category, Application and Specification
6.8.2.1 Product A
6.8.2.2 Product B
6.8.3 CASI Pharmaceuticals, Inc. (USA) Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2012-2017)
6.8.4 Main Business/Business Overview
6.9 AstraZeneca plc (UK)
6.9.2 Angiogenesis Modulators Product Category, Application and Specification
6.9.2.1 Product A
6.9.2.2 Product B
6.9.3 AstraZeneca plc (UK) Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2012-2017)
6.9.4 Main Business/Business Overview
6.10 Eli Lilly and Company (USA)
6.10.2 Angiogenesis Modulators Product Category, Application and Specification
6.10.2.1 Product A
6.10.2.2 Product B
6.10.3 Eli Lilly and Company (USA) Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2012-2017)
6.10.4 Main Business/Business Overview
6.11 F.Hoffmann-La Roche AG (Switzerland)
7 Angiogenesis Modulators Manufacturing Cost Analysis
7.1 Angiogenesis Modulators Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Angiogenesis Modulators
8 Industrial Chain, Sourcing Strategy and Downstream Buyers
8.1 Angiogenesis Modulators Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Angiogenesis Modulators Major Manufacturers in 2016
8.4 Downstream Buyers
9 Marketing Strategy Analysis, Distributors/Traders
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List
10 Market Effect Factors Analysis
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change
11 United States Angiogenesis Modulators Market Size (Value and Volume) Forecast (2017-2022)
11.1 United States Angiogenesis Modulators Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Angiogenesis Modulators Sales Volume Forecast by Type (2017-2022)
11.3 United States Angiogenesis Modulators Sales Volume Forecast by Application (2017-2022)
11.4 United States Angiogenesis Modulators Sales Volume Forecast by Region (2017-2022)
12 Research Findings and Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
List of Tables and Figures
Figure Product Picture of Angiogenesis Modulators
Figure United States Angiogenesis Modulators Market Size (K MT) by Type (2012-2022)
Figure United States Angiogenesis Modulators Sales Volume Market Share by Type (Product Category) in 2016
Figure Angiogenesis Inhibitors Product Picture
Figure Angiogenesis Stimulators Product Picture
Figure Angiogenin Product Picture
Figure Others Product Picture
Figure United States Angiogenesis Modulators Market Size (K MT) by Application (2012-2022)
Figure United States Sales Market Share of Angiogenesis Modulators by Application in 2016
Figure Breast Cancer Examples
Table Key Downstream Customer in Breast Cancer
Figure Colorectal Cancer Examples
Table Key Downstream Customer in Colorectal Cancer
Figure Lung Cancer Examples
Table Key Downstream Customer in Lung Cancer
Figure Prostate Cancer Examples
Table Key Downstream Customer in Prostate Cancer
Figure Others Examples
Table Key Downstream Customer in Others
Figure United States Angiogenesis Modulators Market Size (Million USD) by Region (2012-2022)
Figure The West Angiogenesis Modulators Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Angiogenesis Modulators Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Angiogenesis Modulators Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Angiogenesis Modulators Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Angiogenesis Modulators Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Angiogenesis Modulators Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Angiogenesis Modulators Sales (K MT) and Growth Rate (2012-2022)
Figure United States Angiogenesis Modulators Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Angiogenesis Modulators Market Major Players Product Sales Volume (K MT) (2012-2017)
Table United States Angiogenesis Modulators Sales (K MT) of Key Players/Suppliers (2012-2017)
Table United States Angiogenesis Modulators Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Angiogenesis Modulators Sales Share by Players/Suppliers
Figure 2017 United States Angiogenesis Modulators Sales Share by Players/Suppliers
Figure United States Angiogenesis Modulators Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Angiogenesis Modulators Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Angiogenesis Modulators Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Angiogenesis Modulators Revenue Share by Players/Suppliers
Figure 2017 United States Angiogenesis Modulators Revenue Share by Players/Suppliers
Table United States Market Angiogenesis Modulators Average Price (USD/MT) of Key Players/Suppliers (2012-2017)
Figure United States Market Angiogenesis Modulators Average Price (USD/MT) of Key Players/Suppliers in 2016
Figure United States Angiogenesis Modulators Market Share of Top 3 Players/Suppliers
Figure United States Angiogenesis Modulators Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Angiogenesis Modulators Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Angiogenesis Modulators Product Category
Table United States Angiogenesis Modulators Sales (K MT) by Region (2012-2017)
Table United States Angiogenesis Modulators Sales Share by Region (2012-2017)
Figure United States Angiogenesis Modulators Sales Share by Region (2012-2017)
Figure United States Angiogenesis Modulators Sales Market Share by Region in 2016
Table United States Angiogenesis Modulators Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Angiogenesis Modulators Revenue Share by Region (2012-2017)
Figure United States Angiogenesis Modulators Revenue Market Share by Region (2012-2017)
Figure United States Angiogenesis Modulators Revenue Market Share by Region in 2016
Table United States Angiogenesis Modulators Price (USD/MT) by Region (2012-2017)
Table United States Angiogenesis Modulators Sales (K MT) by Type (2012-2017)
Table United States Angiogenesis Modulators Sales Share by Type (2012-2017)
Figure United States Angiogenesis Modulators Sales Share by Type (2012-2017)
Figure United States Angiogenesis Modulators Sales Market Share by Type in 2016
Table United States Angiogenesis Modulators Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Angiogenesis Modulators Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Angiogenesis Modulators by Type (2012-2017)
Figure Revenue Market Share of Angiogenesis Modulators by Type in 2016
Table United States Angiogenesis Modulators Price (USD/MT) by Types (2012-2017)
Figure United States Angiogenesis Modulators Sales Growth Rate by Type (2012-2017)
Table United States Angiogenesis Modulators Sales (K MT) by Application (2012-2017)
Table United States Angiogenesis Modulators Sales Market Share by Application (2012-2017)
Figure United States Angiogenesis Modulators Sales Market Share by Application (2012-2017)
Figure United States Angiogenesis Modulators Sales Market Share by Application in 2016
Table United States Angiogenesis Modulators Sales Growth Rate by Application (2012-2017)
Figure United States Angiogenesis Modulators Sales Growth Rate by Application (2012-2017)
Table Celgene Corporation (USA) Basic Information List
Table Celgene Corporation (USA) Angiogenesis Modulators Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Celgene Corporation (USA) Angiogenesis Modulators Sales Growth Rate (2012-2017)
Figure Celgene Corporation (USA) Angiogenesis Modulators Sales Market Share in United States (2012-2017)
Figure Celgene Corporation (USA) Angiogenesis Modulators Revenue Market Share in United States (2012-2017)
Table Eisai Co., Ltd. (Japan) Basic Information List
Table Eisai Co., Ltd. (Japan) Angiogenesis Modulators Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Eisai Co., Ltd. (Japan) Angiogenesis Modulators Sales Growth Rate (2012-2017)
Figure Eisai Co., Ltd. (Japan) Angiogenesis Modulators Sales Market Share in United States (2012-2017)
Figure Eisai Co., Ltd. (Japan) Angiogenesis Modulators Revenue Market Share in United States (2012-2017)
Table Amgen, Inc. (USA) Basic Information List
Table Amgen, Inc. (USA) Angiogenesis Modulators Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Amgen, Inc. (USA) Angiogenesis Modulators Sales Growth Rate (2012-2017)
Figure Amgen, Inc. (USA) Angiogenesis Modulators Sales Market Share in United States (2012-2017)
Figure Amgen, Inc. (USA) Angiogenesis Modulators Revenue Market Share in United States (2012-2017)
Table Genentech, Inc. (USA) Basic Information List
Table Genentech, Inc. (USA) Angiogenesis Modulators Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Genentech, Inc. (USA) Angiogenesis Modulators Sales Growth Rate (2012-2017)
Figure Genentech, Inc. (USA) Angiogenesis Modulators Sales Market Share in United States (2012-2017)
Figure Genentech, Inc. (USA) Angiogenesis Modulators Revenue Market Share in United States (2012-2017)
Table GlaxoSmithKline plc (UK) Basic Information List
Table GlaxoSmithKline plc (UK) Angiogenesis Modulators Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure GlaxoSmithKline plc (UK) Angiogenesis Modulators Sales Growth Rate (2012-2017)
Figure GlaxoSmithKline plc (UK) Angiogenesis Modulators Sales Market Share in United States (2012-2017)
Figure GlaxoSmithKline plc (UK) Angiogenesis Modulators Revenue Market Share in United States (2012-2017)
Table Bayer Pharma AG (Germany) Basic Information List
Table Bayer Pharma AG (Germany) Angiogenesis Modulators Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Bayer Pharma AG (Germany) Angiogenesis Modulators Sales Growth Rate (2012-2017)
Figure Bayer Pharma AG (Germany) Angiogenesis Modulators Sales Market Share in United States (2012-2017)
Figure Bayer Pharma AG (Germany) Angiogenesis Modulators Revenue Market Share in United States (2012-2017)
Table Bionomics Ltd. (Australia) Basic Information List
Table Bionomics Ltd. (Australia) Angiogenesis Modulators Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Bionomics Ltd. (Australia) Angiogenesis Modulators Sales Growth Rate (2012-2017)
Figure Bionomics Ltd. (Australia) Angiogenesis Modulators Sales Market Share in United States (2012-2017)
Figure Bionomics Ltd. (Australia) Angiogenesis Modulators Revenue Market Share in United States (2012-2017)
Table CASI Pharmaceuticals, Inc. (USA) Basic Information List
Table CASI Pharmaceuticals, Inc. (USA) Angiogenesis Modulators Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure CASI Pharmaceuticals, Inc. (USA) Angiogenesis Modulators Sales Growth Rate (2012-2017)
Figure CASI Pharmaceuticals, Inc. (USA) Angiogenesis Modulators Sales Market Share in United States (2012-2017)
Figure CASI Pharmaceuticals, Inc. (USA) Angiogenesis Modulators Revenue Market Share in United States (2012-2017)
Table AstraZeneca plc (UK) Basic Information List
Table AstraZeneca plc (UK) Angiogenesis Modulators Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure AstraZeneca plc (UK) Angiogenesis Modulators Sales Growth Rate (2012-2017)
Figure AstraZeneca plc (UK) Angiogenesis Modulators Sales Market Share in United States (2012-2017)
Figure AstraZeneca plc (UK) Angiogenesis Modulators Revenue Market Share in United States (2012-2017)
Table Eli Lilly and Company (USA) Basic Information List
Table Eli Lilly and Company (USA) Angiogenesis Modulators Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Eli Lilly and Company (USA) Angiogenesis Modulators Sales Growth Rate (2012-2017)
Figure Eli Lilly and Company (USA) Angiogenesis Modulators Sales Market Share in United States (2012-2017)
Figure Eli Lilly and Company (USA) Angiogenesis Modulators Revenue Market Share in United States (2012-2017)
Table F.Hoffmann-La Roche AG (Switzerland) Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Angiogenesis Modulators
Figure Manufacturing Process Analysis of Angiogenesis Modulators
Figure Angiogenesis Modulators Industrial Chain Analysis
Table Raw Materials Sources of Angiogenesis Modulators Major Players/Suppliers in 2016
Table Major Buyers of Angiogenesis Modulators
Table Distributors/Traders List
Figure United States Angiogenesis Modulators Sales Volume (K MT) and Growth Rate Forecast (2017-2022)
Figure United States Angiogenesis Modulators Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Angiogenesis Modulators Price (USD/MT) Trend Forecast (2017-2022)
Table United States Angiogenesis Modulators Sales Volume (K MT) Forecast by Type (2017-2022)
Figure United States Angiogenesis Modulators Sales Volume (K MT) Forecast by Type (2017-2022)
Figure United States Angiogenesis Modulators Sales Volume (K MT) Forecast by Type in 2022
Table United States Angiogenesis Modulators Sales Volume (K MT) Forecast by Application (2017-2022)
Figure United States Angiogenesis Modulators Sales Volume (K MT) Forecast by Application (2017-2022)
Figure United States Angiogenesis Modulators Sales Volume (K MT) Forecast by Application in 2022
Table United States Angiogenesis Modulators Sales Volume (K MT) Forecast by Region (2017-2022)
Table United States Angiogenesis Modulators Sales Volume Share Forecast by Region (2017-2022)
Figure United States Angiogenesis Modulators Sales Volume Share Forecast by Region (2017-2022)
Figure United States Angiogenesis Modulators Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
  • Global Pizotifen Market Research Report 2018
    Published: 18-Jul-2018        Price: US 2900 Onwards        Pages: 99
    This report studies the global Pizotifen market status and forecast, categorizes the global Pizotifen market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa. The global Pizotifen market is valued at million US$ in 2017 and will reach million US$ by the end of 2025, growing at a CAGR of during 2018-2025. The major manufacturer......
  • Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or TYRO3 or EC 2.7.10.1) - Pipeline Review, H2 2018
    Published: 17-Jul-2018        Price: US 3500 Onwards        Pages: 35
    Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or TYRO3 or EC 2.7.10.1) - Pipeline Review, H2 2018 Summary Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or TYRO3 or EC 2.7.10.1) pipel......
  • Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) - Pipeline Review, H2 2018
    Published: 17-Jul-2018        Price: US 3500 Onwards        Pages: 37
    Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) - Pipeline Review, H2 2018 Summary Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) - Transglutaminase 2 (TG2) is a member of the transglutaminase family tha......
  • Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Pipeline Review, H2 2018
    Published: 17-Jul-2018        Price: US 3500 Onwards        Pages: 40
    Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Pipeline Review, H2 2018 Summary Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Respiratory syncytial virus G protein is a protein produced by respiratory syncytial virus. It attaches the virion to the host cell membrane by interacting with heparan sulfate. It interacts with host CX3CR1, the receptor for the CX3C chemokine fractalkine, to modulate the immune response and facilitate in......
  • Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Pipeline Review, H2 2018
    Published: 17-Jul-2018        Price: US 3500 Onwards        Pages: 70
    Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Pipeline Review, H2 2018 Summary Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) pipeline Target constitutes close to 15 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report Survival Motor Neuron Protein - Pipeline Review, H2 2018, outlays comprehensive information on the S......
  • NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Pipeline Review, H2 2018
    Published: 17-Jul-2018        Price: US 3500 Onwards        Pages: 65
    NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Pipeline Review, H2 2018 Summary According to the recently published report 'NT 3 Growth Factor Receptor - Pipeline Review, H2 2018'; NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) pipeline Target constitutes close to 7 molecules. ......
  • MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Pipeline Review, H2 2018
    Published: 17-Jul-2018        Price: US 3500 Onwards        Pages: 41
    MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Pipeline Review, H2 2018 Summary MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - MAP kinase-interacting serine/threonine-protein kinase 2 is an enzyme encoded by the MKNK2 gene. It phosphorylates SFPQ/PSF, HNRNPA1 and EIF4E. It plays a role in the response to environmental ......
  • BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H2 2018
    Published: 17-Jul-2018        Price: US 3500 Onwards        Pages: 129
    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H2 2018 Summary According to the recently published report 'BDNF NT 3 Growth Factors Receptor - Pipeline Review, H2 2018'; BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK......
  • Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Pipeline Review, H2 2018
    Published: 17-Jul-2018        Price: US 3500 Onwards        Pages: 48
    Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Pipeline Review, H2 2018 Summary According to the recently published report 'Ephrin Type B Receptor 4 - Pipeline Review, H2 2018'; Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) pipeline Target constitutes close to 6 molecules. Out of which approximately 3 molecules are developed by compa......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs